China Medical System: NDA for the Improved New Drug ZUNVEYL for Alzheimer’s Disease Accepted in China

China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) (“ZUNVEYL” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). The Product is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults.   About Product ZUNVEYL ZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients. As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized […]

Embracing Growth, Celebrating a New Chapter | Singapore and Emerging Markets Pharmaceutical Development Forum Successfully Held

On July 15 2025, to mark the successful secondary listing of China Medical System Holdings Limited (“CMS” or the “Group”) on the Main Board of the Singapore Exchange (“SGX”), SGX and CMS co-hosted the “Singapore and Emerging Markets Pharmaceutical Industry Growth Forum & CMS SGX Secondary Listing Appreciation Dinner”. Held in a grand fashion, the event was held at the Group’s CDMO manufacturing facility, PharmaGend, which is located in Tuas, Singapore.   The event brought together about 150 representatives from local government agencies, multinational pharmaceutical companies, innovative biotech companies, leading investment institutions, and the KOLs in the pharmaceutical industry. Through a series of insightful keynote speeches and panel discussions, guests engaged in in-depth exchanges and shared ideas on various topics, such as the pharmaceutical industry’s development in Singapore and emerging markets across the Asia-Pacific region, the breakthroughs and overseas expansion of Chinese innovative drugs, the globalization strategies, commercialization pathways, as well as ecosystem collaboration of innovative pharmaceutical companies.   The forum began […]

A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today

On the morning of 15 July 2025, China Medical System Holdings Limited (“CMS” or the “Group”) rang the ceremonial bell to mark its official listing on the Singapore Exchange Main Board (Stock Abbreviation: CMS, Stock Code: 8A8).     Nearly one hundred representatives from global professional institutions, shareholders, business partners and employees gathered to witness this strategic moment. Following its successful IPO on the Hong Kong Stock Exchange Main Board in September 2010 , CMS advances with formidable momentum onto the international capital platform, which will attract funds focusing on Asia-Pacific investments and local capital in Southeast Asia to optimize the shareholder structure. This listing also marks a significant milestone for the Group to deepen roots in emerging markets and advance industrial internationalization strategy.   At the listing ceremony, Chairman, Chief Executive Officer and President of CMS, Mr. Lam Kong stated: “The secondary listing in Singapore represents a crucial step in implementing CMS’s Asia-Pacific strategy, demonstrating our commitment to extending China’s market advantages across the entire APAC region while strengthening our presence in Southeast […]

IND Approval: CMS’s Self-developed Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 is Approved for Drug Clinical Trials for Atopic Dermatitis Indication

China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that innovative drug CMS-D001 tablets (“CMS-D001”) self-developed by its subsidiaries, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) together with its subsidiaries, has been granted approval for drug clinical trials by National Medical Products Administration of the People’s Republic of China (“NMPA”) on 11 July 2025. The NMPA grants the consent to conduct a clinical trial evaluating the safety and efficacy of CMS-D001 for the treatment of atopic dermatitis (AD).   CMS-D001 CMS-D001 is a highly selective TYK2 (tyrosine kinase 2) inhibitor. TYK2 is a member of the JAK kinase family, which is an important component in immune cell […]

China Medical System and Xihong Biopharma Jointly Announced: Poly-L-lactic Acid Microparticle Filler Injection was Approved for Marketing in China

China Medical System Holdings Limited (the “Group” or “CMS”) and Jiangsu Xihong Biopharma Co., Ltd. (“Xihong Biopharma”) jointly announced that on July 10, 2025, the registration certificate of the Class Ⅲ medical device, Poly-L-lactic Acid Microparticle Filler Injection (the “Product”), has been approved by the National Medical Products Administration of China (NMPA) (Medical Device Registration Certificate No. 国械注准20253131356), which marks a significant milestone for CMS in the regenerative product field, further expanding its consumer healthcare product portfolio.   Poly-L-lactic Acid Microparticle Filler Injection The Product is approved for deep dermis and subcutaneous layer of nasolabial fold injection for the correction of moderate to severe nasolabial fold wrinkles. Its main component, Poly-L-lactic Acid (PLLA), is the high polymer material that is highly biocompatible and completely degradable, and is widely used in the fields of micro-plastic surgery, sports medicine, neurosurgery, etc., with proven safety and efficacy. PLLA gradually degrades after injection, which […]

CMS: Receipt of Eligibility-To-List Letter from the SGX-ST

On 25 June 2025, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) received an eligibility-to-list letter (“ETL”) from the Singapore Exchange Securities Trading Limited (the “SGX-ST”) in respect of the Proposed Secondary Listing and, subject to fulfilment of the conditions set out therein, the Shares are expected to be listed and to commence trading on the SGX-ST on around 15 July 2025. The ETL is not an indication of the merits of the Proposed Secondary Listing, the Group and/or the Shares.   The Proposed Secondary Listing will not involve issuance of new Shares, and the Shares will continue to be listed and traded on the Hong Kong Stock Exchange thereafter.   The Directors believe that upon completion of the Proposed Secondary Listing on the SGX-ST, the Group will be able to attract funds focusing on Asia-Pacific investments and local capital in Southeast Asia, thereby optimizing the shareholder structure. At the same time, it will also have a more […]

China Medical System Holdings Limited: Proposed Secondary Listing on the Singapore Exchange

The board of directors of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) announces the proposed secondary listing of the Company’s ordinary shares (“Shares”) on the Singapore Exchange Securities Trading Limited (the “SGX-ST”) by way of introduction (the “Proposed Secondary Listing”). The Proposed Secondary Listing, if proceeded, will not involve issuance of new shares, and the Shares will continue to be primarily listed and traded on the Hong Kong Stock Exchange thereafter. The Company has submitted, on a confidential basis, an application to the SGX-ST in relation to the Proposed Secondary Listing. As of the date of this announcement, the Company has not received the eligibility-to-list letter (“ETL”) from the SGX-ST in respect of the Proposed Secondary Listing. On June 24, 2025, the Company received the Notice of Overseas Issuance and Listing Filing (境外發行上市備案通知書) from the China Securities Regulatory Commission (the “CSRC”) in respect of […]

CMS Charity | Lighting Up the Stars for Exceptional Children and Rural Education with Love

As the International Children’s Day approaches, China Medical System Holdings Limited (“CMS”)  has once again partnered with the Charity Association of Shenzhen Nanshan to visit Shenzhen Nanshan Star Exceptional Children Rehabilitation Center and Shenzhen Nanshan Exceptional Children Care Center, donating dedicated funds to both institutions. The donation will be used to purchase toys and teaching aids, upgrade office facilities, and sponsor advanced training for outstanding teachers to enhance the professionalism of special education staff. CMS has continuously supported the growth and development of exceptional children, and is wholeheartedly committed to playing a role in fostering a learning environment brimming with love and warmth for the children. Simultaneously, CMS is actively responding to China’s “Hundreds, Thousands, Tens of Thousands Project,” which aims to promote rural revitalization. Through the Guangdong Education Foundation, CMS has donated a total of 18 sets of laptops and desktop computers to Caojiang No. 2 Middle School in Gaozhou for the construction of a Loving Language Laboratory, enabling students to better […]

CMS Proposes to Spin-off and Separately List the Shares of Dermavon on the Main Board of HKEX

The Company proposes to spin-off and separately list the shares of Dermavon, a subsidiary of the Company, on the Main Board of the Stock Exchange. The Proposed Spin-off, if proceeded, is expected to be implemented through a distribution in specie by the Company of all the shares in Dermavon that it holds to the Shareholders in proportion to their respective shareholding in the Company as of a record date to be determined by the Board for the purpose of ascertaining the Shareholders’ entitlements. The separate listing of the shares of Dermavon on the Stock Exchange constitutes a spin-off of Dermavon by the Company under the Practice Note 15 to the Listing Rules. The Stock Exchange has confirmed that the Company may proceed with the Proposed Spin-off. In connection with the Proposed Spin-off, on 22 April 2025, Dermavon submitted an application to the Stock Exchange for the listing of, and permission […]

China Medical System has been Included in the S&P Global Sustainability Yearbook (China Edition) for the 3rd Consecutive Year

On April 15, 2025, S&P Global officially released the Sustainability Yearbook (China Edition) 2025. China Medical System Holdings Limited (“CMS” or the “Group”) has stood out among over 1,600 Chinese companies with its outstanding performance in environmental, social, and governance (ESG) practices, marking its third consecutive year of inclusion in the Yearbook. Source: S&P Global   CMS has been implementing the concept of sustainable development into its strategy formulation and daily operation, focusing on unmet healthcare needs to provide better treatment solutions for doctors and patients, and striving to improve the accessibility and affordability of pharmaceutical products. At the same time, the Group has been continuously optimizing its internal governance, upholding the bottom line of product responsibility, respecting and empowering employees, and actively participating in public welfare, charity, and environmental protection activities, thus promoting a virtuous cycle of corporate development and responsibility fulfillment.   Through persistent dedication to sustainable development, […]

Restructuring and Breakthroughs: “New CMS” Starts a “New Journey” of Innovation丨CMS(867.HK)2024 Annual Performance Report in One Picture

IND Approval: CMS’s Self-developed Innovative Drug Cardiac Myosin Inhibitor CMS-D003 is Approved for Drug Clinical Trials

China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that innovative drug CMS-D003 capsules (“CMS-D003”) self-developed by the Group has been granted approval for drug clinical trials by National Medical Products Administration of the People’s Republic of China (“NMPA”) on 11 March 2025. The approval was obtained on 12 March 2025. The NMPA grants the Group consent to conduct a clinical trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of CMS-D003 in both healthy adults and adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in China.   CMS-D003 CMS-D003 is a small molecule cardiac myosin inhibitor, which is a targeted therapy for hypertrophic cardiomyopathy. By targeting inhibition of cardiac myosin adenosine triphosphate (ATP) enzymes, it inhibits myosin-actin interactions, reduces myofilament sliding, inhibits myocardial over-contraction, and improves diastolic dysfunction of the heart, thereby alleviating the patient’s clinical symptoms[1]. CMS-D003 demonstrates a short half-life, minimal risk for drug […]